Tela Bio, INC 8-K filings

NASDAQ

21 Mar 2024

TELA

8-K: TELA Bio Reports Record Revenues and Launches New Hernia Fixation Devices

TELA Bio announced record fourth quarter and full year 2023 revenues, along with the U.S. commercial launch of LIQUIFIX hernia mesh fixation devices.

NASDAQ

20 Mar 2024

TELA

Tela Bio, INC

8-K: TELA Bio Sells Distribution Rights for Wound Care Product to MiMedx for Up to $12 Million

TELA Bio has sold the distribution rights for its NIVIS Fibrillar Collagen Pack to MiMedx for an initial payment of $5 million, with potential future payments up to $7 million based on sales performance.